Boy's awesome note reveals perfect survival tips

Don't run away. Picture: ThinkStock. Source: Supplied

THIS little boy hasn't even run away yet but already he's broken one of his main rules: "Don't let anyone see this".

That was point #32 on an extensive list written by a nine-year-old planning his perfect getaway - and how to survive on the lam.

In this awesome series of notes uploaded by Imgur user vwbrenna, the boy known as Jack plots every last detail of his runaway fantasy, stuff.co.nz reports.

And he kid's certainly got an imagination.

Take for instance tip #14: "try to find a new family" and tip #21: "act normal".

Then there are the repeated reminders to use bird's nest as kindling in any fire he'll create along the way.

But at least he's healthy; Jack's #1 tip is this: "Bring lots of food, no junk food". Picture: Imgur Source: Supplied

Picture: Imgur Source: Supplied

Picture: Imgur Source: Supplied

Picture: Imgur Source: Supplied

Picture: Imgur Source: Supplied

Picture: Imgur Source: Supplied

Picture: Imgur Source: Supplied

Picture: Imgur Source: Supplied

View the original article here

Lilly breast cancer drug fails to improve survival in trial

n">(Reuters) - Eli Lilly and Co said its experimental breast cancer drug failed to improve patients' survival without their cancer worsening in a late-stage trial, dashing investors' hopes on one of the company's most talked-about drugs.

Lilly shares fell 5 percent in premarket trade.

The company said it does not plan to submit an approval application for the drug, ramucirumab, for treating advanced breast cancer.

However, a separate trial, testing the drug as a treatment for advanced gastric cancer, met the main goal of improving patients' survival.

Ramucirumab - deemed as one of Lilly's most promising experimental treatments - was being tested in combination with chemotherapy drug docetaxel, and compared with a placebo and docetaxel as initial treatment in patients with advanced breast cancer.

Lilly said it is determining next steps for patients enrolled in the breast cancer trial conducted along with Translational Research in Oncology, an international cancer research group.

Ramucirumab is also being tested in late-stage trials for treating cancers of the colon, lung and liver.

Lilly shares fell 5 percent to $50.14 in trading before the bell. They closed at $52.61 on the New York Stock Exchange on Wednesday.

(Reporting by Esha Dey in Bangalore; Editing by Sriraj Kalluvila)

View the original article here